Do you want to read an article? Please log in or register.
Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management
Gastrointestinal CancerSkin Cancer
Related content
Further Publications
Association between immune-related adverse events and long-term survival outcomes in patients treated with immune checkpoint inhibitors
Eur J Cancer.
Maillet D, Corbaux P, Stelmes JJ, Dalle S, Locatelli-Sanchez M, Perier-Muzet M, Duruisseaux M, Kiakouama-Maleka L, Freyer G, Boespflug A, Péron J
doi: 10.1016/j.ejca.2020.03.017.
Non-Malignant Blood Disorders
Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?
Eur J Cancer.
Michot JM, Lazarovici J, Tieu A, Champiat S, Voisin AL, Ebbo M, Godeau B, Michel M, Ribrag V, Lambotte O
doi: 10.1016/j.ejca.2019.07.014.
Lung, Respiratory and Thoracic Cancer
Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer
JAMA Oncol.
Shankar B, Zhang J, Naqash AR, Forde PM, Feliciano JL, Marrone KA, Ettinger DS, Hann CL, Brahmer JR, Ricciuti B, Owen D, Toi Y, Walker P, Otterson GA, Patel SH, Sugawara S, Naidoo J
doi: 10.1001/jamaoncol.2020.5012.
Further Publications
Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer
JAMA Oncol.
Dolladille C, Ederhy S, Sassier M, Cautela J, Thuny F, Cohen AA, Fedrizzi S, Chrétien B, Da-Silva A, Plane AF, Legallois D, Milliez PU, Lelong-Boulouard V, Alexandre J
doi: 10.1001/jamaoncol.2020.0726.
Radio-Oncology
Safety of Thoracic Radiotherapy in Patients with Prior Immune-Related Adverse Events from Immune Checkpoint Inhibitors
Ann Oncol.
Shaverdian N, Beattie J, Thor M, Offin M, Shepherd AF, Gelblum DY, Wu AJ, Simone CB 2nd, Hellmann MD, Chaft JE, Rimner A, Gomez DR
doi: 10.1016/j.annonc.2020.09.016.
Further Publications
The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry
Eur J Cancer
Ruste V, Goldschmidt V, Laparra A, Messayke S, Danlos FX, Romano-Martin P, Champiat S, Voisin AL, Baldini C, Massard C, Laghouati S, Marabelle A, Lambotte O, Michot JM
doi: 10.1016/j.ejca.2021.08.048
Multiple Myeloma (MM)
Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline
J Clin Oncol
Santomasso BD, Nastoupil LJ, Adkins S, Lacchetti C, Schneider BJ, Anadkat M, Atkins MB, Brassil KJ, Caterino JM, Chau I, Davies MJ, Ernstoff MS, Fecher L, Funchain P, Jaiyesimi I, Mammen JS, Naidoo J, Naing A, Phillips T, Porter LD, Reichner CA, Seigel C, Song JM, Spira A, Suarez-Almazor M, Swami U, Thompson JA, Vikas P, Wang Y, Weber JS, Bollin K, Ghosh M
doi: 10.1200/JCO.21.01992
COMMENTED
Further Publications
Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy
★ 3
Recommended and commented by
Prof. Dr Dr Sacha Rothschild, Faculty Member
Eur J Cancer
Ghisoni E, Wicky A, Bouchaab H, Imbimbo M, Delyon J, Gautron Moura B, Gérard CL, Latifyan S, Özdemir BC, Caikovski M, Pradervand S, Tavazzi E, Gatta R, Marandino L, Valabrega G, Aglietta M, Obeid M, Homicsko K, Mederos Alfonso NN, Zimmermann S, Coukos G, Peters S, Cuendet MA, Di Maio M, Michielin O
doi: 10.1016/j.ejca.2021.03.010
Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse events
J Immunother Cancer.
Läubli H, Balmelli C, Kaufmann L, Stanczak M, Syedbasha M, Vogt D, Hertig A, Müller B, Gautschi O, Stenner F, Zippelius A, Egli A, Rothschild SI
doi: 10.1186/s40425-018-0353-7.